Search

Your search keyword '"AstraZeneca PLC -- Product development"' showing total 1,606 results
Start Over Descriptor "AstraZeneca PLC -- Product development" Topic clinical trials
1,606 results on '"AstraZeneca PLC -- Product development"'

1. AstraZeneca: TEZSPIRE Met Both Co-primary Endpoints in the Phase III WAYPOINT Trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Arts and entertainment industries, Tezspire (Medication) -- Product development
Abstract

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen's TEZSPIRE (tezepelumab) demonstrated a statistically [...]

Published
2024

2. Arcus announces clinical trial collaboration pact to evaluate casdatifan combo

Subjects
AstraZeneca PLC -- Product development, Medical research, Medicine, Experimental, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Arcus Biosciences (RCUS) announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan, Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients [...]

Published
2024

3. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Author

Li, Zheqi, Filho, Otto Metzger, Viale, Giuseppe, dell'Orto, Patrizia, Russo, Leila, Goyette, Marie-Anne, Kamat, Avni, Yardley, Denise A., Abramson, Vandana Gupta, Arteaga, Carlos L., Spring, Laura M., Chiotti, Kami, Halsey, Carol, Waks, Adrienne G., King, Tari A., Lester, Susan C., Bellon, Jennifer R., Winer, Eric P., Spellman, Paul T., Krop, Ian E., and Polyak, Kornelia

Subjects
Merck & Company Inc. -- Product development, Genentech Inc. -- Product development, Novartis AG -- Product development, Agilent Technologies Inc. -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, RNA sequencing, Biotechnology industry -- Product development, Pertuzumab, B cells, RNA, Clinical trials, Instrument industry -- Product development, Breast cancer, Pharmaceutical industry -- Product development, Health care industry
Abstract

BACKGROUND. HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR). METHODS. To investigate cellular and molecular differences among tumors according to HER2 heterogeneity and pCR, we performed RNA sequencing and ERBB2 FISH of 285 pretreatment and posttreatment tumors from 129 patients in this T-DM1+P neoadjuvant trial. A subset of cases was also subject to NanoString spatial digital profiling. RESULTS. Pretreatment tumors from patients with pCR had the highest level of ERBB2 mRNA and ERBB signaling. HER2 heterogeneity was associated with no pCR, basal-like features, and low ERBB2 expression yet high ERBB signaling sustained by activation of downstream pathway components. Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K pathway enrichment and luminal features. HET tumors showed minimal treatment-induced transcriptomic changes compared with non-HET tumors. Immune infiltration correlated with pCR and HER2-HET status. CONCLUSION. Resistance mechanisms in HET and non-HET tumors are distinct. HER2-targeting antibodies have limited efficacy in HET tumors. Our results support the stratification of patients based on HET status and the use of agents that target downstream components of the ERBB signaling pathway in patients with HET tumors. TRIAL REGISTRATION. ClinicalTrials.gov NCT02326974. FUNDING. This study was funded by Roche and the National Cancer Institute., Introduction Breast cancer is one of the most prevalent and life-threatening malignancies in women worldwide (1). Breast cancer is a heterogeneous disease clinically classified on the basis of the expression [...]

Published
2024
Full Text
View/download PDF

4. AstraZeneca says ADJUVANT BR.31 Phase III trial did not achieve primary endpoint

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Lung cancer, Non-small cell, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Imfinzi (Medication) -- Product development
Abstract

High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group, showed Imfinzi did not achieve statistical significance for the primary endpoint of disease-free survival, [...]

Published
2024

5. AstraZeneca announces positive results from ECHO phase III trial of Calquence in combo with bendamustine & rituximab to treat patients with untreated mantle cell lymphoma

Subjects
AstraZeneca PLC -- Product development, Non-Hodgkin's lymphomas -- Care and treatment, Clinical trials, Bendamustine, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Calquence (Medication) -- Product development
Abstract

Positive results from the ECHO phase III trial showed AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) [...]

Published
2024

6. AstraZeneca announces results from ECHO Phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Bendamustine, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Calquence (Medication) -- Product development
Abstract

Results from the ECHO Phase III trial showed AstraZeneca's CALQUENCE in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and showed a [...]

Published
2024

7. AstraZeneca presents results from LAURA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Lung cancer, Non-small cell, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Tagrisso (Medication) -- Product development
Abstract

Results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth [...]

Published
2024

8. AstraZeneca presents results from ADRIATIC Phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Imfinzi (Medication) -- Product development
Abstract

Results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to [...]

Published
2024

9. Datopotamab deruxtecan shows clinically meaningful OS improvement vs. chemotherapy in patients with advanced nonsquamous NSCLC in TROPION-Lung01 phase III trial

Subjects
AstraZeneca PLC -- Product development, Operating systems -- Product development, Chemotherapy, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Cancer -- Care and treatment -- Chemotherapy, Pharmaceutical industry -- Product development, 64-bit operating system, 32-bit operating system, Operating system, Pharmaceuticals and cosmetics industries
Abstract

High-level overall survival (OS) results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favoured datopotamab deruxtecan (Dato-DXd) compared to docetaxel [...]

Published
2024

10. AstraZeneca announces positive results from ADRIATIC phase III trial of Imfinzi in patients with limited-stage small cell lung cancer

Subjects
AstraZeneca PLC -- Product development, Lung cancer, Small cell -- Prognosis -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Imjudo (Medication) -- Product development, Imfinzi (Medication) -- Product development
Abstract

Positive high-level results of the ADRIATIC phase III trial showed AstraZeneca's Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) [...]

Published
2024

11. AstraZeneca releases ADRIATIC Phase III trial results on IMFINZI

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Lung cancer, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Imfinzi (Medication) -- Product development
Abstract

Results of the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in [...]

Published
2024

12. Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Prostate cancer, Metastasis, Hormones, Clinical trials, Business, international, Truqap (Medication) -- Product development
Abstract

Cambridge: AstraZeneca has issued the following press release: Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy [...]

Published
2024

13. TRUQAP[R] (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Prostate cancer, Metastasis, Hormones, Androgens, Clinical trials, Fulvestrant -- Product development, Business, Business, international
Abstract

First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer WILMINGTON, Del. -- Positive high-level results from the CAPItello-281 Phase III trial showed that [...]

Published
2024

14. KOMET Phase III trial met primary endpoint

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Koselugo (Medication) -- Product development
Abstract

Helsinki: AstraZeneca PLC has issued the following news release: Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with neurofibromatosis type 1 [...]

Published
2024

15. Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

Subjects
AstraZeneca PLC -- Product development, Nasal polyps -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Tezspire (Medication) -- Product development
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) [...]

Published
2024

16. Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Airsupra (Medication) -- Product development, Diseases, Care and treatment, Product development, Clinical trials, Type 2 diabetes -- Care and treatment, Glucocorticoids, Pharmaceutical industry -- Product development, Asthma -- Care and treatment, Corticosteroids
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint, demonstrating a statistically [...]

Published
2024

17. Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Subjects
AstraZeneca PLC -- Product development, Cancer -- Care and treatment, Clinical trials, Carcinoma, Renal cell, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

* Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) * This is the [...]

Published
2024

18. AstraZeneca's Tagrisso with the addition of chemotherapy showed favourable trend in OS in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 phase III trial

Subjects
AstraZeneca PLC -- Product development, Operating systems -- Product development, Metastasis, Pemetrexed -- Product development, Chemotherapy, Clinical trials, Lung cancer, Non-small cell, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, 64-bit operating system, 32-bit operating system, Operating system, Pharmaceuticals and cosmetics industries, Tagrisso (Medication) -- Product development
Abstract

Results from the FLAURA2 phase III trial showed AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in [...]

Published
2024

19. DUO-E phase III trial of Lynparza & Imfinzi demonstrates strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with pMMR advanced or recurrent endometr

Subjects
AstraZeneca PLC -- Product development, Medical research, Medicine, Experimental, Endometrial cancer -- Care and treatment, Chemotherapy, Clinical trials, Cancer -- Care and treatment -- Chemotherapy, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Imfinzi (Medication) -- Product development, Lynparza (Medication) -- Product development
Abstract

Latest analysis of the results from the DUO-E phase III trial showed Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) demonstrated an improvement [...]

Published
2024

20. AstraZeneca's Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, stage III EGFR-mutated lung cancer in LAURA phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Epidermal growth factor, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Tagrisso (Medication) -- Product development
Abstract

Positive high-level results from the LAURA phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, [...]

Published
2024

21. Positive high-level results from Japan phase III trial of acoramidis in adults with transthyretin-mediated ATTR-CM showed consistency with global ATTRibute-CM phase III trial

Subjects
Alexion Pharmaceuticals Inc. -- Product development, AstraZeneca PLC -- Product development, Clinical trials, Adults, Heart, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Positive high-level results from the Japan phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency to those in the global BridgeBio Pharma, Inc. (BridgeBio) ATTRibute-CM [...]

Published
2024

22. AIM ImmunoTech starts patient enrolment in phase 1b/2 study of Ampligen in combo with AstraZeneca's Imfinzi to treat late-stage pancreatic cancer

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Cancer -- Care and treatment -- Research, Clinical trials, Pancreatic cancer -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Ampligen (Medication) -- Product development, Imfinzi (Medication) -- Product development
Abstract

AIM ImmunoTech Inc., an immuno-pharma company, announced that the first subject has been enrolled at Erasmus Medical Center (Erasmus MC) in a phase 1b/2 clinical trial combining AIM's Ampligen (rintatolimod) [...]

Published
2024

23. AstraZeneca: TEZSPIRE Met Both Co-primary Endpoints in the Phase III WAYPOINT Trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international, Telecommunications industry, Tezspire (Medication) -- Product development
Abstract

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen's TEZSPIRE (tezepelumab) demonstrated a statistically [...]

Published
2024

24. Alexion, AstraZeneca Rare Disease and Merck Highlight Positive Topline Results from the Phase 3 KOMET Trial

Subjects
AstraZeneca PLC -- Product development, Merck Research Laboratories -- Product development, Diseases -- United States -- United Kingdom, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international, Telecommunications industry, Koselugo (Medication) -- Product development
Abstract

Alexion, AstraZeneca Rare Disease and Merck, known as MSD outside of the United States and Canada, reported positive topline results from the Phase 3 KOMET trial, which is the largest, [...]

Published
2024

25. Non-Cystic Fibrosis Bronchiectasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring

Subjects
Boehringer Ingelheim GmbH -- Product development, AstraZeneca PLC -- Product development, Insmed Inc. -- Product development, Medical research, Medicine, Experimental, Cystic fibrosis, Clinical trials, Bronchiectasis, Business, Business, international
Abstract

M2 PRESSWIRE-September 24, 2024-: Non-Cystic Fibrosis Bronchiectasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring (C)1994-2024 M2 [...]

Published
2024

26. Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Product development, Clinical trials, Riociguat, Business research, Treprostinil -- Product development, Nintedanib, Lung diseases, Pharmaceutical industry -- Product development, Pirfenidone, Business -- Research
Abstract

M2 PRESSWIRE-September 16, 2024-: Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:15092024 Interstitial Lung [...]

Published
2024

27. Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Clinical trials, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Pharmaceutical industry -- Product development, Business, international
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca's proprietary computational pathology [...]

Published
2024

28. Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Chemotherapy, Clinical trials, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Cancer -- Chemotherapy -- Research, Pharmaceutical industry -- Product development, Business, international, Imfinzi (Medication) -- Product development
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab [...]

Published
2024

29. United Kingdom : Clinical trials for chronic kidney disease

Subjects
AstraZeneca PLC -- Product development, Medical research, Medicine, Experimental, Chronic kidney failure, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Product development
Abstract

Clinical trials to accelerate research into treating chronic kidney disease will be strengthened as a result of a new partnership between the Scottish Government, academia and industry. NHS Scotland, AstraZeneca [...]

Published
2024

30. FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results

Subjects
United States. Food and Drug Administration, AstraZeneca PLC -- Product development, Lung cancer, Small cell -- Care and treatment, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Pharmaceutical industry -- Product development, Business, international, Imfinzi (Medication) -- Product development
Abstract

Cambridge, United Kingdom: AstraZeneca Pharmaceutical company has issued the following press release: The Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca's Imfinzi (durvalumab) met the [...]

Published
2024

31. Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Lung diseases, Treprostinil -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 9, 2024-: Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:09072024 Interstitial Lung [...]

Published
2024

32. Asthma Clinical Trials Analysis 2024: Therapies, FDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Subjects
Novartis AG -- Product development, AstraZeneca PLC -- Product development, Sanofi S.A. -- Product development, Business -- Research, Respiratory agents, Biological products -- Product development, Drug approval, Clinical trials, Pharmaceutical industry -- Product development, Asthma, Business, Business, international
Abstract

M2 PRESSWIRE-July 2, 2024-: Asthma Clinical Trials Analysis 2024: Therapies, FDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:02072024 * Asthma companies are [...]

Published
2024

33. Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Subjects
Pfizer Inc. -- Product development, Boehringer Ingelheim GmbH -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, Business -- Research, Diseases -- Germany -- United States -- United Kingdom, Fatty liver, Clinical trials, Type 2 diabetes, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 2, 2024-: Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS [...]

Published
2024

34. AstraZeneca drug for early lung cancer fails Phase 3 trial

Subjects
AstraZeneca PLC -- Product development, Lung cancer -- Drug therapy, Clinical trials, Pharmaceutical industry -- Product development, General interest, Imfinzi (Medication) -- Product development
Abstract

An AstraZeneca drug aimed at treating early stage lung cancer has failed its latest clinical trials. The Anglo-Swedish drug giant said Imfinzi, known as durvalumab, did not meet the main [...]

Published
2024

35. AstraZeneca to discontinue STABILIZE-CKD and DIALIZE-Outcomes phase III trials for Lokelma

Subjects
AstraZeneca PLC -- Product development, Biological products -- Product development, Clinical trials, Kidney diseases, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due to substantially increased enrolment timelines and low [...]

Published
2023

36. AstraZeneca's Imfinzi plus bevacizumab meets primary endpoint for PFS in liver cancer eligible for embolisation in EMERALD-1 phase III trial

Subjects
AstraZeneca PLC -- Product development, Liver cancer, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Positive high-level results from the EMERALD-1 phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in [...]

Published
2023

37. ZENITH-CKD phase IIb trial of zibotentan/dapagliflozin combo demonstrates significant albuminuria reduction in patients with CKD and proteinuria

Subjects
AstraZeneca PLC -- Product development, Dapagliflozin, Clinical trials, Albumin, Kidney diseases -- Care and treatment, Pharmaceuticals and cosmetics industries
Abstract

Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone. After 12 [...]

Published
2023

38. AstraZeneca: Enhertu demonstrated meaningful survival in Phase II trial

Subjects
AstraZeneca PLC -- Product development, Biological products -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Enhertu (Medication) -- Product development
Abstract

Results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit [...]

Published
2023

39. AstraZeneca reports 'positive' results from TROPION-Breast01 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

AstraZeneca (AZN) says 'positive' results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan, or Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or [...]

Published
2023

40. FLAURA2 phase III trial result shows AstraZeneca's Tagrisso plus chemotherapy reduces disease progression in brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at bas

Subjects
AstraZeneca PLC -- Product development, Metastasis -- Care and treatment, Pemetrexed -- Product development, Chemotherapy, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Tagrisso (Medication) -- Product development
Abstract

Results from a prespecified exploratory analysis of the FLAURA2 phase III trial showed AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy demonstrated a 42% improvement in central nervous system (CNS) [...]

Published
2023

41. DUO-E phase III trial shows Imfinzi plus Lynparza reduces the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

Subjects
AstraZeneca PLC -- Product development, Endometrial cancer, Chemotherapy, Clinical trials, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Imfinzi (Medication) -- Product development, Lynparza (Medication) -- Product development
Abstract

Positive results from the primary analysis of the DUO-E phase III trial showed that Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib), both [...]

Published
2023

42. Soft Tissue Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Subjects
Bayer AG -- Product development, Takara Bio Inc. -- Product development, Incyte Corp. -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Sarcoma, Biotechnology industry -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 28, 2024-: Soft Tissue Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:28062024 Soft Tissue Sarcoma [...]

Published
2024

43. Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer

Subjects
AstraZeneca PLC -- Product development, Imfinzi (Medication) -- Product development, Product development, Clinical trials, Durvalumab -- Product development, Small cell lung cancer, Pharmaceutical industry -- Product development, Non-small cell lung cancer, Lung cancer, Small cell, Lung cancer, Non-small cell
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group (CCTG), showed Imfinzi (durvalumab) [...]

Published
2024

44. Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Imfinzi (Medication) -- Product development, Care and treatment, Patient outcomes, Product development, Clinical trials, Durvalumab -- Product development, Bladder cancer -- Patient outcomes -- Care and treatment, Chemotherapy, Pharmaceutical industry -- Product development, Cancer patients -- Care and treatment -- Patient outcomes, Cancer -- Chemotherapy
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically [...]

Published
2024

45. IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Cancer patients -- Care and treatment -- Patient outcomes, Bladder cancer -- Complications and side effects -- Patient outcomes -- Care and treatment, Chemotherapy, Clinical trials, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, News, opinion and commentary, Imjudo (Medication) -- Complications and side effects -- Product development, Imfinzi (Medication) -- Complications and side effects -- Product development
Abstract

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 25, 2024-- Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful [...]

Published
2024

46. Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer

Subjects
AstraZeneca PLC -- Product development, Metastasis, Chemotherapy, Clinical trials, Cancer -- Chemotherapy, Breast cancer, Pharmaceutical industry -- Product development, Business, international, Truqap (Medication) -- Product development
Abstract

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: The CAPItello-290 Phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic [...]

Published
2024

47. Update on CAPItello-290 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Metastasis, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Truqap (Medication) -- Product development
Abstract

Helsinki: AstraZeneca PLC has issued the following news release: The CAPItello-290 Phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative [...]

Published
2024

48. CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

Subjects
AstraZeneca PLC -- Product development, Non-Hodgkin's lymphomas -- Complications and side effects -- Care and treatment, Clinical trials, Bendamustine -- Complications and side effects, Pharmaceutical industry -- Standards -- Product development, News, opinion and commentary, Calquence (Medication) -- Complications and side effects -- Product development
Abstract

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 16, 2024-- Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically [...]

Published
2024

49. IMFINZI(r) (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

Subjects
AstraZeneca PLC -- Product development, Lung cancer, Small cell, Cancer -- Prevention, Immunotherapy, Clinical trials, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Imfinzi (Medication) -- Product development
Abstract

WILMINGTON: AstraZeneca has issued the following news release: Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI(r) (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual [...]

Published
2024

50. Age-related Macular Degeneration Pipeline Insights, 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Companies | Novartis, Alexion Pharmaceuticals, AstraZeneca

Subjects
Novartis AG -- Product development, AstraZeneca PLC -- Product development, Pipe lines, Business -- Research, Macular degeneration, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 3, 2024-: Age-related Macular Degeneration Pipeline Insights, 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Companies | Novartis, Alexion Pharmaceuticals, AstraZeneca (C)1994-2024 M2 COMMUNICATIONS RDATE:03062024 As [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results